Hanmi's Amosartan plus & Twotops plus cause the same formulation, whether or not listed. The Ministry of Health and Welfare announced the plan to revalue the addition in November 2020, and said that IMD will maintain its addition if the number of companies with the same product registered, individual single agents, complex agents, and administrative routes, ingredients, and formulations is less than one. Amosartan plus was scheduled to end its addition on September 1, but it was maintained with such an improved new drug preferential measure because there was no other drugs. The Company does in law would be unfair to do. This is because Telmidipine Plus was registered in March 2020 before the announcement of the add